TY  - JOUR

T1  - MP70-10 FURTHER CHARACTERIZATION OF THE EFFECTS OF PRIOR OR NO PRIOR DOCETAXEL THERAPY ON CRPC PATIENTS WITH BONE METASTASES RECEIVING RA-223 IN THE PHASE 3 ALSYMPCA TRIAL

JO  - Journal of Urology

PY  - 2014/04/01

AU  - Shore N

AU  - Sartor O

AU  - Vogelzang N

AU  - Hoskin P

AU  - Nilsson S

AU  - Coleman R

AU  - Parker C

AU  - Wahba M

AU  - Staudacher K

ED  - 

DO  - DOI: 10.1016/j.juro.2014.02.2209

PB  - Ovid Technologies (Wolters Kluwer Health)

VL  - 191

IS  - 4S

Y2  - 2025/10/10

ER  -